Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario

A population-based retrospective cohort study

Rates of opioid use disorder (OUD) have been rising and has led to accelerated rates of opioid-related deaths. Opioid agonist therapy (OAT) with methadone or buprenorphine/naloxone is an effective treatment option for people with OUD. OAT prevents opioid withdrawal, manages cravings, and lowers the risk of fatal overdose and opioid-related emergency care compared to other treatments.

This study examined treatment duration among people initiating methadone or buprenorphine/naloxone in Ontario, Canada, and whether retention varies according to age, sex, and urban/rural residence.

Access the full article:

Journal Article
Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.